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Progress in Vaccination Against Cancer 
(PIVAC) 2002 was held in Nottingham, 
U K , July 18-20, 2002. Over 100 dele-
gates from 17 countries attended this sci-
entific event. The following review sum-
marizes the main issues arising from the 
presentations at the conference. 
Identification & characterization of 
tumor antigens 
The identification of immunogenic mole-
cules which are overexpressed in malig-
nant tissues, but not in essential normal 
cells, such as brain, lung, heart, liver and 
kidney, is crucial for the development of 
cancer vaccines. The serological identifi-
cation of tumor antigens by a recom-
binant expression cloning (SEREX) 
approach was discussed during the meet-
ing. D Schadendorf, Heidelberg, Ger-
many, reported that they had identified 
several antigens by immunoscreening of 
cDNA libraries constructed from normal 
testis and cutaneous lymphomas with sera 
from patients with cutaneous lymphoma. 
Some of these antigens were only 
expressed in testis and tumor tissues and 
also reacted with sera from patients with 
cutaneous lymphoma [l]. A Miles, Not-
tingham, UK, applied a similar approach 
to identify prostatic carcinoma antigens 
and isolated three antigens which were 
overexpressed in normal testes and can-
cerous tissues, as determined by real-time 
reverse transcriptase polymerase chain 
reaction (RT-PCR). SEREX-defined anti-
gens were also found in acute myeloid 
leukemia (B Guinn, London, UK) [2]. 
Application of mass spectrometric 
analytical techniques in conjunction 
with Ciphergen protein chip technology, 
coupled with trainable artificial neural 
network programs, may allow the identi-
fication of validated biomarkers corre-
lated with disease progression, treatment 
success or tumor escape. These biomark-
ers warrant further characterization to 
assess their suitability as potential thera-
peutic targets (S Mian, Nottingham, 
U K , J Tolson, Tubingen, Germany) [3]. 
The wide expression of the human tel-
omerase catalytic subunit (hTERT) in 
tumors makes it an interesting universal 
candidate antigen for cancer immuno-
therapy. G Gaudernack, Oslo, Norway, 
has used several new epitopes of hTERT 
that can elicit both CD4 and CD8 cell 
responses against hTERT in a clinical 
Phase I trial in patients with advanced 
pancreatic cancer, non-small cell lung 
cancer and melanoma. No serious 
adverse effects related to the treatment 
have been observed and 75% of patients 
who received high-dose vaccine demon-
strated an immune response measured 
either by delayed-type hypersensitivity 
(DTH) reaction or in vitro tests. Further-
more, a survival advantage was observed 
for patients receiving the high-dose vac-
cine compared with those receiving the 
lower dose [4]. 
Proteins encoded by bcr/abl fusion 
genes generated by t(9;22) transloca-
tion in chronic myelogenous leukemia 
(CML) patients are not expressed in 
normal cells. G Pawelec, Tubingen, 
Germany, described synthetic peptides 
representing sequences encompassing 
the break point region of both bcr/abl 
and abl/bcr that were immunogenic for 
both CD4 and CD8 cells in vitro. Ik 
Dodi, London, U K , reported on C M L -
specific peptides eluted from human 
leukocyte antigen (HLA)-A3 or H L A -
B8 K652 (CML cell line) transfectants 
as well as from C M L cells isolated from 
HLA-A3 patients. Tetramers of H L A -
A3 and HLA-B8 with the correspond-
ing eluted peptides were produced and 
used to detect antigen-specific cytotoxic 
T-lymphocytes (CTLs) from HLA-A3 
and HLA-B8 patients at various stages 
of the disease and treatment [5]. 
A combination of vaccines targeting 
both tumor endothelial and epithelial 
cells may lead to vascular collapse and 
increase extravasation leading to tumor 
regression. Tie-2 is a receptor tyrosine 
kinase overexpressed in tumor endothe-
lial cells. Both CD4 and CD8 epitopes 
within Tie-2 were identified. CD8 
epitopes can stimulate C T L responses 
in HLA-A2 transgenic mice and kill 
endothelial cells overexpressing Tie-2. 
CD4 epitopes can stimulate a T h l 
response in vitro. CD55 is overex-
pressed in tumor cells and a human 
anti-idiotypic antibody, 105AD7, that 
mimics the CD55 antigen has been 
produced. Colorectal tumor patients 
immunized with 105AD7 showed T-
cell blastogenesis against tumor cells 
expressing CD55 and a significant 
increase in tumor cell apoptosis (LG 
Durrant, Nottingham, UK) [6]. 
D E Speiser, Lausanne, Switzerland, 
has vaccinated melanoma patients with 
Melan-A/MART-1 peptides. The vac-
cines were well tolerated. One of 21 
patients showed disease stabilization and 
two out of 21 patients who had the 
strongest activation and expansion of 
tumor antigen-specific T-cells experi-
enced regression of skin, lymph nodes 
and lung metastases [7]. J M Rojas, Not-
tingham, U K , reported that major histo-
compatibility complex (MHC) class II 
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epitopes derived from p53 and gplOO 
were immunogenic in a transgenic 
mouse model and demonstrated that 
H L A - D R transgenic mice represent a 
suitable model for the discovery of 
M H C class II-restricted epitopes derived 
from tumor antigens. 
Dendritic cell-based vaccination 
Dendritic cells (DCs) play a central role 
in the immune system. Without optimal 
D C antigen-presenting function there 
can be no antitumor immunity. How-
ever, it is important to note that DCs 
that present the relevant MHC-peptide 
complexes qualify as potential targets and 
are at risk of being eliminated by the 
CTLs they have activated. Immature 
DCs are indeed susceptible to C T L -
induced killing, but the mature DCs 
activated by Anti-CD40 or lipopolysac-
charide (LPS) are resistant to this effect. 
Protection is achieved by expression of a 
serine protease inhibitor (SPI)-6 and its 
human homolog PI-9 induced by Anti-
CD40 and LPS (R Offringa, Leiden, The 
Netherlands) [8]. 
A M Jackson, Leeds, U K , described 
recombinant mycobacteria expressing 
tumor antigens able to infect and cause 
marked maturation of DCs, resulting in 
cytokine secretion and increased T-cell 
stimulatory capacity. E Kaminski, Ply-
mouth, UK, reported that autologous T-
cells treated with interleukin (IL) -15 
prior to culture with tumor lysate-pulsed 
DCs, exhibited a significant increase in 
T-cell proliferation, interferon (IFN)-y 
secretion and specific cytotoxicity to tar-
get cells. HS Pandha, London, UK, has 
developed a method of culturing then 
cryopreserving, monocyte-derived DCs 
after pulsing with irradiated allogenic 
prostatic cancer cell lysate. This process 
increased DC maturation and thus 
enhanced their antigen-presenting capa-
bility. In the study, 14 patients with met-
astatic prostatic cancer received the D C 
vaccines (a Phase I/II clinical trial) and 
four experienced a PSA response: two 
with an arrest in PSA levels and two 
showing reduction in PSA levels. 
V Cerundolo, Oxford, UK, discussed 
the strategies that could generate a broad 
and long-lasting antitumor-specific 
immunity. They engineered a string of 
HLA-A2 and -Al-restricted melanoma 
epitopes which were cloned into naked 
plasmid D N A , vaccinia virus, modified 
vaccinia Ankara virus (MVA) and Sem-
liki forest virus (SFV) and vaccinated 
HLA-A2 transgenic mice with different 
combinations of the polyepitope con-
structs. Their results demonstrated that 
competition for antigen recognition at 
the surface of antigen-presenting cells 
(APCs) may significantly skew the 
immune response and this competition 
needs to be taken into account for the 
development of vaccination strategies to 
optimally induce polyvalent C T L 
response. They identified two alternative 
protocols for inducing polyvalent C T L 
response, based on the injection of either 
increasing numbers of APCs infected 
with vaccinia virus encoding the poly-
epitope construct, or a mixture of viruses 
each coding a separate antigen [9]. 
P Straten, Copenhagen, Denmark, 
described T C R clonotype mapping uti-
lizing RT-PCR and denaturing gradient 
gel electrophoresis (DGGE). Using these 
sensitive assays it was demonstrated that 
predominant T-cell clones infiltrating 
melanoma tissue do not reflect T-cell 
populations expanded in vitro from the 
same tissue. This questions the interpre-
tation and potential importance of data 
obtained on cultured TILs. However, the 
application of D G G E has shown a corre-
lation between circulating T-cell clones 
and TILs during IL-2 therapy. 
Tumor escape from immune surveillance 
Tumor cells develop various strategies to 
escape immune surveillance and effector 
cells also express negative regulatory recep-
tors which provides further examples of the 
double-edged sword of immunotherapy. 
Finding ways of preventing tumor escape 
by multiple strategies will be the main chal-
lenge for immunotherapy of cancer. KJ 
Malmberg, Stockholm, Sweden, described 
how hydrogen peroxide (H2O2), released 
by tumor infiltrating macrophages, can 
impair the cytokine production and func-
tion of T- and natural killer (NK) cells. 
Exogenous supplied antioxidants, such as 
high doses of dietary vitamin E, may pro-
tect the immune cells from die attack of 
H2O2 by increasing CD4/CD8 ratio and 
IL-2 production. He also pointed out that 
IFN-y treatment of ovarian carcinoma cells 
protected them from lysis by CTL. This 
phenomenon was dependent on the 
enhanced signaling via CD94/NKG2A 
receptors expressed on the T-cells [10]. On 
the other hand, IFN-y is essential for tumor 
resistance in animal models including the 
Stat-6 knockout model described by S 
Ostrand-Rosenberg, Baltimore, USA [11]. 
M Ahmad, Nottingham, U K , 
reported that direct intratumor injec-
tion of disabled herpes simplex viruses, 
DISC/HSV/mGM-CSR into estab-
lished tumors induced tumor rejection 
in 40-60% of treated animals (regres-
sor), while the remaining mice had 
progressive tumors (progressor). To 
identify the mechanisms responsible 
for the failure of immunotherapy, they 
examined whether the APCs of pro-
gressor mice were functional and 
induced a C T L response - they 
reported that the APCs from the pro-
gressor mice did not support C T L gen-
eration. They suggest that either the 
presence of suppressor elements in the 
progressor paranchymal A P C fraction 
or the APCs from progressor mice do 
not effectively present antigens to 
CTLs [12]. As mentioned in the section 
on DC-based vaccination, DCs protect 
themselves against lysis by the CTLs 
they induced by expressing PI-9/SPT6. 
Unfortunately, a variety of human and 
murine tumor cells also express PI-9/ 
SPI-6, resulting in the resistance of 
tumor cells to CTL-mediated killing. 
Loss or downregulation of TAP 
expression prevents presentation of the 
tumor antigens on the surface of tumor 
cells and therefore allows them to avoid 
recognition by CTLs. WA Jefferies, Van-
couver, Canada, described how transfec-
tion of mouse melanoma B16F10 (TAP-
deficient) cells with vaccinia vector car-
rying TAP1 could enhance tumor-spe-
cific T-cell generation and reduce tumor 
burden in mice. Inclusion of TAP in 
cancer therapy might provide a general 
method for increasing immune 
responses against tumors regardless of 
the antigenic complement of tumor or 
the M H C haptotypes of the host [13]. 
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